By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sequella, Inc. 

9610 Medical Center Drive, Suite 200

Rockville  Maryland  20850  U.S.A.
Phone: 301-762-7776 Fax: 301-762-7778



Company News
Vaccine-Fixated Pfizer Inc. (PFE) Licenses Out TB Drug to Sequella, Inc. 7/17/2013 6:51:41 AM
Biotech Venture Fund's Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed From Sequella, Inc. 12/19/2012 9:50:54 AM
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella, Inc.'s Antibiotic, SQ109, for Tuberculosis 7/26/2012 9:54:00 AM
Sequella, Inc. Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia to Maxwell Biotech Venture Fund Subsidiary; Deal Valued at Over $100 Million to the Parties 4/25/2011 9:52:49 AM
Sequella, Inc. Awarded $4.6 Million in New National Institutes of Health (NIH) Grants to Expand Anti-Infectives Pipeline 4/4/2011 9:14:18 AM
John H. Friedman of Easton Capital Investment Group Joins Sequella, Inc. Board of Directors 1/31/2011 9:13:30 AM
Sequella, Inc. Files IND and Receives FDA Go-ahead for Phase 2 Trial of SQ109 in Helicobacter pylori-associated Duodenal Ulcers 12/6/2010 11:33:29 AM
Sequella, Inc. Receives International Support for Phase 2 Clinical Trials of SQ109, its Lead Antitubercular Drug Candidate 10/18/2010 12:00:32 PM
Sequella, Inc.: Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 7/26/2010 11:11:26 AM
Sequella, Inc. and National Institutes of Health (NIH) Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications 11/17/2009 9:58:39 AM